Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 5/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29679063 | 1.00 | MEN1 (0.44) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL9971647 | 1.00 | MEN1 (0.44) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL13077420 | 1.00 | MEN1 (0.44) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL13137474 | 0.97 | MEN1 (0.44) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL18179121 | 0.92 | MEN1 (0.42) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL15445093 | 0.92 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL23728812 | 0.91 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL17364289 | 0.91 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL21069640 | 0.91 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 | |
| SCHEMBL21071644 | 0.91 | MEN1 (0.49) | MEN1GAAKMT2ATDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3391056-B1 | CHROMOGENIC PEROXIDASE SUBSTRATES | AGILENT TECHNOLOGIES INC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11466314-B2 | Chromogenic peroxidase substrates | AGILENT TECHNOLOGIES, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20200157613-A1 | CHROMOGENIC PEROXIDASE SUBSTRATES | DAKO DENMARK APS (DK) | 2020-05-21 | — | — | US | disclosed |
| US-20170175178-A1 | CHROMOGENIC PEROXIDASE SUBSTRATES | DAKO DENMARK APS (DK) | 2017-06-22 | — | — | US | disclosed |
| EP-2046375-B1 | METHODS AND COMPOSITIONS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORIAL TARGETING | MASSACHUSETTS GEN HOSPITAL (US) | 2017-04-05 | — | — | EP | disclosed |
| US-8993295-B2 | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting | THE GENERAL HOSPITAL CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993295-B2 | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting | THE GENERAL HOSPITAL CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993295-B2 | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting | THE GENERAL HOSPITAL CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-7893253-B2 | Aminating reducing sugar; mass spectrometry | MERCK PATENT GMBH (DE) | 2011-02-22 | — | — | US | disclosed |
| US-20100055761-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING | THE GENERAL HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055761-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING | THE GENERAL HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055761-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING | THE GENERAL HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| EP-1846765-B1 | SOLID-PHASE OLIGOSACCHARIDE TAGGING: A TECHNIQUE FOR MANIPULATION OF IMMOBILIZED CARBOHYDRATES | MERCK PATENT GMBH (DE) | 2009-05-27 | — | — | EP | disclosed |
| US-20080305070-A1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080227092-A1 | Solid-Phase Oligosaccharide Tagging: a Technique for Manipulation of Immobilized Carbohydrates | MERCK PATENT GESELLSCHAFT (DE) | 2008-09-18 | — | — | US | disclosed |
| US-20070166276-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | ENZON PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070166276-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | ENZON PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170175178-A1 | CHROMOGENIC PEROXIDASE SUBSTRATES | MPO, TPO, TYR | MEN1 3360/4885GAA 101/4885KMT2A 4046/4885 |
| US-11466314-B2 | Chromogenic peroxidase substrates | MPO, TPO, TYR | MEN1 3504/4885GAA 114/4885KMT2A 4064/4885 |
| US-20200157613-A1 | CHROMOGENIC PEROXIDASE SUBSTRATES | MPO, TPO, TYR | MEN1 3504/4885GAA 114/4885KMT2A 4064/4885 |
| US-20070166276-A1 | Releasable polymeric conjugates based on aliphatic biodegradable linkers | CD44, PAICS, ALG1 | MEN1 3290/4885GAA 540/4885KMT2A 3190/4885 |
| US-20080305070-A1 | RELEASABLE POLYMERIC CONJUGATES BASED ON ALIPHATIC BIODEGRADABLE LINKERS | CD44, PAICS, PCBP1 | MEN1 3971/4885GAA 1027/4885KMT2A 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.